Episodes

  • Empowering Pharmacists in the Management of Patients With Urothelial Cancer

    Empowering Pharmacists in the Management of Patients With Urothelial Cancer
    Sep 3 2025
    Sherry Vogt, PharmD, BCOP; and Megan Hinkley, PharmD, MBA, BCOP, discuss how pharmacists play a crucial role in managing patients with bladder cancer through treatment selection, patient education, adverse effect monitoring, and the evolving landscape of therapies including traditional chemotherapy, immunotherapy, and antibody-drug conjugates like enfortumab vedotin plus pembrolizumab.
    Show More Show Less
    46 mins
  • Personalizing Progress: New Data Shaping Care in Central Precocious Puberty

    Personalizing Progress: New Data Shaping Care in Central Precocious Puberty
    Aug 29 2025
    Panelists discuss how central precocious puberty involves early activation of the hypothalamic-pituitary-gonadal axis before age 8 in girls and age 9 in boys, requiring individualized treatment decisions based on factors like growth velocity, bone age advancement, and psychosocial impact, with GnRH agonist therapies available in multiple formulations (injections and implants) that effectively suppress puberty while preserving final height potential and having reassuring long-term safety profiles for bone health and fertility outcomes.
    Show More Show Less
    43 mins
  • Empowering Pharmacists in the Management of Patients With Urothelial Cancer

    Empowering Pharmacists in the Management of Patients With Urothelial Cancer
    Aug 27 2025
    Sherry Vogt, PharmD, BCOP; and Megan Hinkley, PharmD, MBA, BCOP, discuss how pharmacists play a crucial role in managing patients with bladder cancer through treatment selection, patient education, adverse effect monitoring, and the evolving landscape of therapies including traditional chemotherapy, immunotherapy, and antibody-drug conjugates like enfortumab vedotin plus pembrolizumab.
    Show More Show Less
    47 mins
  • Clinical Insights on Dyskinesia and Tremor in Parkinson’s Disease

    Clinical Insights on Dyskinesia and Tremor in Parkinson’s Disease
    Aug 25 2025
    Panelist discusses how distinguishing between dyskinesia (choreoform, dance-like movements) and tremor in Parkinson's disease is crucial for treatment decisions, as modern therapeutic options including extended-release amantadine, continuous subcutaneous delivery systems, and advanced formulations can now effectively manage both motor fluctuations and troublesome dyskinesias simultaneously.
    Show More Show Less
    35 mins
  • Exploring Recent Developments in the Treatment of Prostate Cancer

    Exploring Recent Developments in the Treatment of Prostate Cancer
    Aug 8 2025
    Jack Andrews, MD; Alicia Morgans, MD, MPH; and Ashley Ross MD, PhD, discuss how trial design, inclusion criteria, and end points like radiographic progression-free survival vs overall survival impact clinical decision-making in prostate cancer treatment, emphasizing the importance of quality of life data and the shift from using ADT alone as standard care toward combination therapies in prostate cancer management.
    Show More Show Less
    39 mins
  • Exploring Recent Developments in the Treatment of Prostate Cancer

    Exploring Recent Developments in the Treatment of Prostate Cancer
    Aug 6 2025
    Jack Andrews, MD; Alicia Morgans, MD, MPH; and Ashley Ross MD, PhD, discuss how trial design, inclusion criteria, and end points like radiographic progression-free survival vs overall survival impact clinical decision-making in prostate cancer treatment, emphasizing the importance of quality of life data and the shift from using ADT alone as standard care toward combination therapies in prostate cancer management.
    Show More Show Less
    31 mins
  • B Cells as a Treatment Target in Myasthenia Gravis

    B Cells as a Treatment Target in Myasthenia Gravis
    Aug 4 2025
    Ali Habib, MD, and Arjun Seth, MD, discuss how B-cell–targeted therapies represent a promising upstream treatment approach for myasthenia gravis that could provide more sustained efficacy compared with current downstream treatments like complement inhibitors and FcRn antagonists, with CD19-targeting agents like inebilizumab showing particular promise in clinical trials for both acetylcholine receptor and MuSK antibody subtypes.
    Show More Show Less
    28 mins
  • Advancing Pharmacist Engagement in Biliary Tract Cancer: Disease State and Treatment Considerations

    Advancing Pharmacist Engagement in Biliary Tract Cancer: Disease State and Treatment Considerations
    Jul 1 2025
    Courtney Cavalieri, PharmD, BCOP, and Kenneth Tham, PharmD, BCOP, discuss how pharmacists play a crucial role in managing biliary tract cancer patients by providing expertise on biomarker testing, treatment selection between targeted therapies like FGFR and HER2 inhibitors, developing monitoring protocols for unique toxicities such as hyperphosphatemia, and educating patients on side effect management to optimize treatment outcomes in this rare cancer type.
    Show More Show Less
    32 mins